دورية أكاديمية
أعرض في EDS

Modulation of PD-L1 by Astragalus polysaccharide attenuates the induction of melanoma stem cell properties and overcomes immune evasion.

التفاصيل البيبلوغرافية
العنوان: Modulation of PD-L1 by Astragalus polysaccharide attenuates the induction of melanoma stem cell properties and overcomes immune evasion.
المؤلفون: Yu H; Institute of Clinical Immunology, Yue-yang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China., Ding G; Institute of Clinical Immunology, Yue-yang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China., Gong Q; Institute of Clinical Immunology, Yue-yang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China., Ma J; Institute of Clinical Immunology, Yue-yang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China., Zhao Y; Institute of Clinical Immunology, Yue-yang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China., Wang Y; Institute of Clinical Immunology, Yue-yang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China., Qiao X; Institute of Clinical Immunology, Yue-yang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China., Cheng X; Institute of Clinical Immunology, Yue-yang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China. xdcheng_8@yeah.net.
المصدر: BMC cancer [BMC Cancer] 2024 Aug 21; Vol. 24 (1), pp. 1034. Date of Electronic Publication: 2024 Aug 21.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: B7-H1 Antigen*/metabolism , Neoplastic Stem Cells*/drug effects , Neoplastic Stem Cells*/metabolism , Neoplastic Stem Cells*/immunology , Polysaccharides*/pharmacology , Melanoma, Experimental*/drug therapy , Melanoma, Experimental*/immunology , Melanoma, Experimental*/metabolism , Melanoma, Experimental*/pathology, Animals ; Mice ; Tumor Escape/drug effects ; Cell Line, Tumor ; Mice, Inbred C57BL ; Humans ; Skin Neoplasms/drug therapy ; Skin Neoplasms/pathology ; Skin Neoplasms/immunology ; Skin Neoplasms/metabolism ; Melanoma/drug therapy ; Melanoma/metabolism ; Melanoma/pathology ; Melanoma/immunology ; Astragalus Plant/chemistry ; Immune Evasion
مستخلص: Background: Melanoma is a highly aggressive form of skin cancer. The existence of cancer stem cells (CSCs) and tumor immune evasion are two major causes of melanoma progression, but no effective treatment has been found at present. Astragalus polysaccharide (APS) is a principal active component derived from Astragalus membranaceus, showing anti-tumor effects in various tumors including melanoma. However, the underlying mechanism is still unclear.
Methods: The regulation of APS on self-renewal ability and CSC markers expression in melanoma stem cells (MSCs) was measured by tumor sphere formation and tumorigenicity assays, RT-qPCR, and western blot. Flow cytometry was conducted to evaluate the activation of immune system by APS in melanoma mice. Further, the mechanism was explored based on PD-L1 overexpression and knock-down B16 cells.
Results: APS attenuated the tumor sphere formation of MSCs in vitro as well as the tumorigenicity in vivo. It also decreased the expression of CD133, BMI1 and CD47. Based on the PD-L1 overexpression and knock-down B16 cells, it was confirmed that APS inhibited the induction of MSCs by down-regulating PD-L1 expression. Meanwhile, APS increased the infiltration of CD4 + and CD8 + T cells in tumor tissues because of its inhibitory effect on PD-L1.
Conclusions: APS inhibited MSC induction and overcame tumor immune evasion through reducing PD-L1 expression. This study provided compelling evidence that APS could be a prospective therapeutic agent for treating melanoma.
(© 2024. The Author(s).)
References: Nutrients. 2019 Sep 20;11(10):. (PMID: 31547048)
Oncogene. 2022 Feb;41(8):1100-1113. (PMID: 35034965)
Cells. 2021 Jun 29;10(7):. (PMID: 34209829)
Int J Med Sci. 2020 Mar 26;17(7):939-945. (PMID: 32308547)
Biomed Rep. 2021 Jun;14(6):52. (PMID: 33884195)
Exp Ther Med. 2022 Oct 18;24(6):722. (PMID: 36340608)
Int J Cancer. 2017 Oct 1;141(7):1402-1412. (PMID: 28614911)
Oncotarget. 2016 Jun 7;7(23):33498-511. (PMID: 27172898)
J Cell Physiol. 2019 Dec;234(12):21642-21661. (PMID: 31102292)
Immunooncol Technol. 2022 Jan 17;13:100070. (PMID: 35754851)
Am J Cancer Res. 2020 Mar 01;10(3):727-742. (PMID: 32266087)
Nature. 2001 Nov 1;414(6859):105-11. (PMID: 11689955)
Eur J Pharmacol. 2022 Feb 5;916:174726. (PMID: 34954232)
Am J Transl Res. 2020 May 15;12(5):1640-1657. (PMID: 32509166)
Cancers (Basel). 2019 Dec 06;11(12):. (PMID: 31817719)
Oncoimmunology. 2020 Mar 3;9(1):1729299. (PMID: 32313717)
J Cell Physiol. 2019 Jun;234(6):8381-8395. (PMID: 30417375)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Neoplasia. 2019 Feb;21(2):185-196. (PMID: 30591423)
Cytokine. 2022 Sep;157:155968. (PMID: 35872504)
J Clin Pathol. 2018 Mar;71(3):189-194. (PMID: 29097600)
Annu Rev Immunol. 2005;23:515-48. (PMID: 15771580)
BMC Cancer. 2022 Nov 30;22(1):1240. (PMID: 36451148)
Gan To Kagaku Ryoho. 2019 May;46(5):850-854. (PMID: 31189802)
Phytomedicine. 2023 Apr;112:154667. (PMID: 36842218)
J Cell Physiol. 2020 Feb;235(2):790-803. (PMID: 31286518)
Int Immunopharmacol. 2024 Jan 5;126:111303. (PMID: 38043269)
Cell Commun Signal. 2023 Nov 3;21(1):315. (PMID: 37924094)
Cancer Sci. 2021 Oct;112(10):4050-4063. (PMID: 34289209)
Oncol Lett. 2021 Jul;22(1):566. (PMID: 34113394)
Cancer Lett. 2019 May 28;450:1-13. (PMID: 30776481)
Cells. 2021 Sep 08;10(9):. (PMID: 34572009)
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7. (PMID: 22451913)
Front Cell Dev Biol. 2021 Jun 21;9:692940. (PMID: 34235155)
J Invest Dermatol. 2022 Aug;142(8):2055-2060. (PMID: 35339277)
Cancer Lett. 2008 Sep 8;268(1):98-109. (PMID: 18486325)
Clin Exp Immunol. 2014 Oct;178(1):79-85. (PMID: 24894428)
Theranostics. 2020 Oct 25;10(26):11950-11962. (PMID: 33204322)
Semin Cancer Biol. 2019 Dec;59:221-235. (PMID: 31265892)
Front Pharmacol. 2020 Mar 24;11:349. (PMID: 32265719)
معلومات مُعتمدة: 82304779 the National Natural Science Foundation of China; YYKC-2021-01-154 the Science and Technology Innovation Project of Shanghai University of Traditional Chinese Medicine; 2021yygm02 the Scientific Research Project in Yue Yang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine; 2021LK089 the Planned Science Program of the Shanghai University of Traditional
فهرسة مساهمة: Keywords: Astragalus polysaccharide; Cancer stem cells; Immune evasion; Melanoma; Programmed cell death ligand 1
المشرفين على المادة: 0 (B7-H1 Antigen)
0 (Polysaccharides)
0 (Cd274 protein, mouse)
تواريخ الأحداث: Date Created: 20240821 Date Completed: 20240821 Latest Revision: 20240824
رمز التحديث: 20240826
مُعرف محوري في PubMed: PMC11340040
DOI: 10.1186/s12885-024-12788-4
PMID: 39169294
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-2407
DOI:10.1186/s12885-024-12788-4